Trace Biosciences had never filed an IND. With no regulatory function, no prior submission, and a lean team, their IND cleared the FDA inside the initial 30-day review window with minimal back and forth.
In this session, Connor Barth, Co-founder and CEO of Trace, sits down with Weave Head of Marketing Molly Tobin to walk through how they did it and what comes next.
You’ll hear where AI accelerated the work, where their own expertise had to lead, and what they’d do differently next time.